Detalles de la búsqueda
1.
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Antimicrob Agents Chemother
; 66(6): e0175121, 2022 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502922
2.
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
Front Immunol
; 15: 1394644, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38863717
3.
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Infect Dis Ther
; 12(9): 2321-2335, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751019
4.
Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
Patient
; 15(1): 131-143, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180035
5.
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
AIDS
; 35(7): 1061-1072, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33946085
6.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lancet HIV
; 7(11): e740-e751, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33128903
7.
8.
Design of diverse and focused combinatorial libraries using an alternating algorithm.
J Chem Inf Comput Sci
; 43(6): 1916-21, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-14632440
9.
Gestaçäo na adolescência / Adoles ant pregnancy
Rev. Bras. Med. - Caderno de Ginecologia & Obstetrícia
; 57: 15-22, jul. 2000. ilus
Artículo
en Portugués
| SES-SP, SESSP-ACVSES | ID: biblio-1066401
Resultados
1 -
9
de 9
1
Próxima >
>>